FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08225 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 第 1 頁 共 10 頁 v 1.2.0 FF301 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國醫療集團有限公司 (以「萬全醫療集團」名稱在香港經營業務) (於開曼群島註冊成立之有限公司) 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08225 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完備性亦無 發表聲明，並表明不會就本公告全部或任何部份內容或因倚賴該等內容而引致之任何損失承擔任何責任。 China Health Group Inc. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 本公司預計於 2026 年 1 月 5 日或之前，向股東寄發載有本次持續關連交易詳情、獨立董事委員 會推薦函、獨立財務顧問意見函及股東特別大會通告的通函。 除本公告所補充披露的資訊外，原公告的其他內容維持不變。 承董事會命 中國醫療集團有限公司 郭夏 主席 香港，二零二五年十二月十六日 於本公告日期，董事會成員包括二名執行董事，分別為郭夏先生及郭瑞萌先生；一名非執行董事，為張麗博 士；及四名獨立非執行董事，分別為倪彬暉博士、伍霜駟先生、郭彤博士及劉娜女士。 本公告載有根據 GEM 上市規則規定須提供有關本公司資料的詳情，董事願就本公佈共同及個別地承擔全部責 任。各董事在作出一切合理查詢後確認，就彼等所知及所信，本公佈所載的資料在各重大方面乃準確完整,無 ...

Core Viewpoint - China Medical Group (08225) has announced a new framework service agreement with Mr. Guo Xia, extending the term of the 2022 service agreement until December 31, 2025, with annual caps set for the years ending December 31, 2025, 2026, and 2027 [1] Group 1 - The new framework service agreement is established to renew the previous service agreement from 2022 [1] - The company has set annual caps for the fiscal years ending December 31 for 2025, 2026, and 2027 [1] - Hongbo Capital Limited has been appointed as an independent financial advisor to provide advice on the new framework service agreement and annual caps to the company's independent board committee and independent shareholders [1]

Group 1 - The company announced a new framework service agreement with Mr. Guo Xia, extending the term of the 2022 service agreement until December 31, 2025 [1] - The agreement sets annual caps for the years ending December 31, 2025, December 31, 2026, and December 31, 2027 [1] - The board has appointed Hongbo Capital Limited as an independent financial advisor to provide advice on the new framework service agreement and annual caps to the company's independent board committee and independent shareholders [1]

Core Viewpoint - China Medical Group (08225) has announced a new framework service agreement with Mr. Guo Xia, extending the term of the 2022 service agreement until December 10, 2025, and setting annual caps for the years ending December 31, 2025, 2026, and 2027 [1] Group 1 - The new framework service agreement is intended to renew the previous service agreement established in 2022 [1] - The company has appointed Hongbo Capital Limited as an independent financial advisor to provide advice to the independent board committee and independent shareholders regarding the new framework service agreement and annual caps [1] - Hongbo Capital Limited is a licensed corporation authorized to conduct regulated activities under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明不會就本公佈全部或任何部份內容或因倚賴 該等內容而引致之任何損失承擔任何責任。 CHINAHEALTHGROUPINC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號:08225) （1）持續關聯交易：新框架服務協議；及 （2）委任獨立財務顧問 獨立董事委員會及獨立股東的 獨立財務顧問 新框架服務協議 茲提述中國醫療集團有限公司（以下簡稱"本公司"）於二零二二年五月十一日就二零 二二年服務協議發佈的公告，根據該協議，本公司同意向關聯方附屬公司提供上市後臨 床研究、醫學科研及醫學市場服務。 往交易金額 二零二三財年：6,117,000 元人民幣 二零二四財年：8,101,000 元人民幣 釐定年度上限的基準 二零二五財年、二零二六財年、二零二七財年的年度上限乃考慮到： 於二零二五年十二月十日（交易時段後），本公司與郭夏先生訂立新框架服務協議，以 續展二零二二年服務協議的期限；並確定截至二零二五年十二月三十一日、二零二六年 十二月三十一 ...

FF301 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國醫療集團有限公司 (以「萬全醫療集團」名稱在香港經營業務) (於開曼群島註冊成立之有限公司) 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08225 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額 ...

Core Viewpoint - The company has reported a total accounts receivable of RMB 128 million as of December 31, 2024, with adequate impairment provisions made according to accounting standards, primarily arising from routine business operations [1] Group 1: Accounts Receivable Recovery Efforts - The company has actively pursued the recovery of receivables since the annual report disclosure, implementing tailored strategies based on the debtor's situation [1] - For related party receivables, the company has established a special working mechanism and has successfully recovered a total of RMB 11.0869 million as of November 30, 2025, with legal arbitration initiated for outstanding amounts [1] - For non-related party receivables, the company has reached agreements with cooperative clients, resulting in additional recoveries of RMB 4.4514 million, with ongoing repayment plans [1] Group 2: Measures for Difficult Receivables - For receivables that are harder to recover, the company has legally included relevant debtors in the list of dishonest executors and will closely monitor their asset status for actionable leads [2] - The company has established an "Accounts Receivable Management Committee" led by the finance department to enhance operational fund quality and strengthen internal controls from credit assessment to payment term management [2] Group 3: Future Plans - The company will continue to take all necessary legal and compliant measures to maximize receivable recovery, including ongoing negotiations, enforcing arbitration judgments, and preparing civil lawsuits [2] - Regular progress reports will be provided to the board, and the company will fulfill its information disclosure obligations in accordance with exchange rules [2]

Core Viewpoint - The company has reported a total accounts receivable of RMB 128 million as of December 31, 2024, with adequate impairment provisions made according to accounting standards, primarily arising from routine business operations [1] Group 1: Collection Efforts - For related party receivables, the company has established a special working mechanism and has successfully recovered RMB 11.0869 million by November 30, 2025, with ongoing legal proceedings for unrecovered amounts [1] - For non-related party receivables, the company has reached agreements with cooperative clients, resulting in additional recoveries of RMB 4.4514 million, with repayment plans being executed steadily [2] - For clients with long overdue accounts or operational difficulties, the company has engaged third-party professionals for assessment and initiated legal procedures to protect its rights [2] Group 2: Internal Management Optimization - The company has established an "Accounts Receivable Management Committee" led by the finance department to enhance collection efforts and has strengthened internal controls from customer credit assessment to payment term management to prevent new risks [3] Group 3: Future Plans - The company will continue to take all necessary legal and compliant measures to maximize the recovery of receivables, including ongoing negotiations, arbitration execution, and civil litigation preparations, with regular progress reports to the board [4]